FDA OKs Medtronic's third HF (heart failure) device:
This article was originally published in Clinica
The US FDA has given Medtronic the go-ahead to market its third cardiac resynchronisation therapy (CRT) product for treating heart failure (HF). The InSync III cardiac resynchronisation therapy system features a new function called "sequential biventricular pacing", which allows physicians to independently programme and control the sequence of contractions of both ventricles of the heart. The ability to adjust the pacing sequence of the ventricles can help doctor's improve the heart's performance, Medtronic says.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.